Analytical Method Development for USP Related Compounds in Paclitaxel Using an Agilent Poroshell 120 PFP

Importance of the Topic

Analysis of related impurities in paclitaxel is crucial for ensuring drug safety and efficacy. Regulatory guidelines from the United States Pharmacopeia (USP) set strict requirements for detecting and quantifying closely related compounds. Advances in column technology, such as superficially porous pentafluorophenyl (PFP) phases, offer improved selectivity and faster turnaround for quality control in pharmaceutical laboratories.

Objectives and Overview of the Study

This application note describes:

• Development of an HPLC method for USP related compounds in paclitaxel using an Agilent Poroshell 120 PFP column (4.6×250 mm, 4 µm).
• Method transfer to a narrower Poroshell 120 PFP column (3.0×100 mm, 2.7 µm) to reduce analysis time and solvent consumption.
• Evaluation of system suitability, selectivity, and compliance with USP requirements.

Methodology and Instrumentation

The analysis was performed on an Agilent 1290 Infinity LC system equipped with a binary pump, autosampler, thermostatted column compartment, and diode array detector (227 nm). Two column formats were compared:

• Poroshell 120 PFP, 4.6×250 mm, 4 µm
• Poroshell 120 PFP, 3.0×100 mm, 2.7 µm

The mobile phase comprised water and acetonitrile with 0.5 % acetic acid. Gradient conditions were adjusted for each column to achieve optimal separation at 30 °C.

Key Results and Discussion

Selectivity tests demonstrated that the PFP phase resolved positional isomers and polar impurities more effectively than a conventional C18 stationary phase. On the 4.6 mm column, resolution between impurity A, impurity B, and paclitaxel exceeded USP thresholds (Rs ≥ 1.0). System suitability parameters (relative retention, resolution, and RSD) met all criteria.

Transferring the method to the 3.0 mm column reduced run time from 80 to 32 minutes while maintaining a resolution of 2.2 between critical peaks. Solvent consumption decreased by over 60 %. All USP system suitability requirements remained satisfied.

Benefits and Practical Applications

The optimized PFP-based method offers:

• Enhanced selectivity for aromatic and halogenated impurities.
• Shorter analysis time and lower solvent usage on narrow-bore columns.
• Straightforward method transfer without compromising USP compliance.

These improvements support high-throughput quality control and routine batch release testing in pharmaceutical development and manufacturing.

Future Trends and Potential Applications

Continued evolution of superficially porous column chemistries will enable even faster separations and higher resolution for complex impurity profiles. Integration with automated method development software can streamline robustness testing and regulatory validation. Similar approaches may be extended to other critical drug substances and their related compounds, advancing overall analytical efficiency.

Conclusion

The Agilent Poroshell 120 PFP column series effectively meets USP requirements for related compound analysis in paclitaxel. Method transfer to a narrower, higher-efficiency column substantially reduces analysis time and solvent use while preserving resolution and system suitability. This workflow enhances productivity in pharmaceutical quality control laboratories.

References

1. Anon. USP Paclitaxel, United States Pharmacopeia 35 NF 30. United States Pharmacopeia, Rockville, MD, USA.
2. Long W., Horton J. Analysis of Positional Isomers with Agilent Poroshell 120 PFP Columns; Agilent Technologies Application Note, 5991-4373EN, 2014.
3. Fu R., Zhang L. Analysis of Positional Isomers in Lapatinib with Agilent Poroshell 120 PFP Columns; Agilent Technologies Application Note, 5991-5262EN, 2014.
4. Long W., Brooks A., Zou Y. Improved Simvastatin Analysis Using Agilent ZORBAX Eclipse Plus C18 Columns; Agilent Technologies Application Note, 5990-3883EN, 2009.